Dendritic cells for the immunotherapy of cancer.

Dendritic cells for the immunotherapy of cancer. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Dendritic cells for the immunotherapy of cancer. Abstract Text:

Dendritic cells for the immunotherapy of cancer. Publishing Authors By Initials

For similar neoplasms research abstracts see: neoplasms research

PUBMED ID PMID:

MEDLINE DATE:

Dendritic cells for the immunotherapy of cancer. Journal Published:

PUBLICATION TYPE: Review

Journal: Clinical oncology (Royal College of Radiologists (

VOLUME: 14

Page Numbers: 185-92

Journal Abbreviation: Clin Oncol (R Coll Radiol)

ISSN: 0936-6555

DAY: 10

MONTH: Jun

YEAR: 2002

Dendritic cells for the immunotherapy of cancer. Information

Number of References: 33

LANGUAGE: eng

NlmUniqueID: 9002902

Dendritic cells for the immunotherapy of cancer. Keywords Mesh Terms:

KEYWORDS: Neoplasms

MESH TERMS: therapy

Chemical & Substance for Abstract: Dendritic cells for the immunotherapy of cancer. Information

Substance Name: Antigens, Neoplasm

Registry Number: 0

Grant and Affiliation Information for Dendritic cells for the immunotherapy of cancer.

AFFILIATION: Imperial Cancer Research Fund, St James's University Hospital, Leeds, UK.

Country: England

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Clin Oncol (R Coll Radiol)

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Dendritic cells for the immunotherapy of cancer Related Publications

• Cancer gene therapy: Part 1. Vector development and regulation of gene expression.
• Cancer gene therapy: Part 2. Candidate transgenes and their clinical development.
• Dendritic cells for the immunotherapy of cancer.
• Exploiting synergies between radiation and oncolytic viruses.
• Induction of hsp70-mediated Th17 autoimmunity can be exploited as immunotherapy for metastatic prostate cancer.
• Loading of oncolytic vesicular stomatitis virus onto antigen-specific T cells enhances the efficacy of adoptive T-cell therapy of tumors.
• Purging metastases in lymphoid organs using a combination of antigen-nonspecific adoptive T cell therapy, oncolytic virotherapy and immunotherapy.
• Synergy of adoptive T-cell therapy and intratumoral suicide gene therapy is mediated by host NK cells.
• Treg Depletion-enhanced IL-2 Treatment Facilitates Therapy of Established Tumors Using Systemically Delivered Oncolytic Virus.
• Unbiased selection of bone marrow derived cells as carriers for cancer gene therapy.
• VSV-G pseudotyped, MuLV-based, semi-replication-competent retrovirus for cancer treatment.